Dapoxetine (PriligyTM, Johnson and Johnson, Raritan, NJ) is the first and only product licensed for the treatment of premature ejaculation (PE) in menaged 18–64 years. At present, dapoxetine is licensed in ten countries, including several countries in Europe, and Mexico, South Korea, and NewZealand.1,2 PE is the most common sexual dysfunction in men, with a global prevalence estimated to be between 20% and 40%..
By proceeding you are confirming that you are a healthcare professional..
Whilst the history is complicated, all you really need to know is that Dapoxetine is the basic name of the drug. Priligy is the brand nameyou’ll see advertised and written on packets of pills..
In addition, PEaffects numerous aspects of a man's life, including sexual confidence, interpersonal relationships, and the sexual satisfaction of both partners5..
Randomized, double blind, placebo-controlled trials have confirmed the efficacy of dapoxetine for the treatment of PE. Different dosage hasdifferent impacts on different type of PE. Dapoxetine 60 mg significantly improves the mean intravaginal ejaculation latency time (IELT) comparedto that of dapoxetine 30 mg in men with lifelong PE, but there is no difference in men with acquired PE. Dapoxetine, given 1–3 hours beforesexual episode, prolongs IELT, increases the sense of control and sexual satisfaction in men of 18 to 64 years of age with PE. Since PE is associatedwith personal distress, interrelationship difficulty, dapoxetine provides help for men with PE to overcome this condition. Because lack of specificapproval treatment for PE in the US and some other countries, other SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, and citalopram havebeen used as off label drugs to treat PE. Waldinger's meta analysis shows that the use of these conventional antidepressants increasing IELT from twoto ninefold above base line in comparison of three to eightfold when dapoxetine is used. However, these SSRIs must be taken daily in order toachieve meaningful efficacy, and the long half-life increases the risk of the drug accumulation and as a consequence increased of adverse effects suchas decreasing sexual libido and causing erectile dysfunction. Dapoxetine, on the other hand, is a fast-acting SSRI. It is rapidly absorbed andeliminated from the body within a few hours. This favorable pharmacokinetics minimizes the risk of the drug's accumulation in the body, and thereforereducing side effects...
Il farmaco non deve essere assunto dai soggetti con accertata ipersensibilità al principio attivo. Altre controindicazioni sono rappresentate dallainsufficienza cardiaca (classe II-IV NYHA), dai disturbi della conduzione (blocco AV di secondo o terzo grado), da una cardiopatia ischemica ovalvolare di rilievo. Non indicato anche in caso di insufficienza epatica di grado moderato o grave, trattamento concomitante con Inibitori dellemonoamino ossidasi (IMAO), trattamento concomitante con farmaci inibitori del CYP3A4, ad esempio ketoconazolo, itraconazolo, ritonavir, saquinavir,telitromicina ed altri..
Currently Dapoxetine has been approved and marketed in over 50 countries, including: Sweden, Finland, Austria, Portugal, Germany, Italy, Spain,Mexico, South Korea, New Zealand, Australia, France, Malaysia, Philippines, Argentina and Uruguay..
The first contemporary multivariate evidence-baseddefinition of lifelong PE was developed in 2008 by a panel of international experts, convened by the International Society for Sexual Medicine (ISSM),who agreed that the diagnostic criteria necessary to define PE are time from penetration to ejaculation, inability to delay ejaculation and negativepersonal consequences from PE. This panel defined lifelong PE as a male sexual dysfunction characterized by ‘ejaculation which always ornearly always occurs prior to or within about one minute of vaginal penetration, the inability to delay ejaculation on all or nearly all vaginalpenetrations, and the presence of negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexualintimacy’ [McMahon et al. 2008]..